As of June 24, 2025, Hansa Biopharma AB (HNSA.ST) reports a EV/EBITDA of -4.25.
EV/EBITDA evaluates a company's total value relative to its earnings before interest, taxes, depreciation, and amortization, useful for comparing firms with different capital structures.
Comparing Hansa Biopharma AB's EV/EBITDA to Peers
To better understand Hansa Biopharma AB's position, it's useful to compare its EV/EBITDA against industry peers. Below are selected comparisons:
| Company | EV/EBITDA |
|---|---|
| Hansa Biopharma AB (HNSA.ST) | -4.25 |
| Bonesupport Holding AB (BONEX.ST) | 104.80 |
| Mabion SA (MAB.WA) | 85.76 |
| Formycon AG (FYB.DE) | 61.27 |
| Probi AB (PROB.ST) | 35.44 |
| Biogaia AB (BIOG B.ST) | 22.03 |
Compared to its competitors, Hansa Biopharma AB's EV/EBITDA is among the lowest compared to peers, which may indicate undervaluation or market concerns about future performance.